Castleman disease is an uncommon lymphoproliferative disorder characterized as either unicentric or multicentric. Unicentric Castleman disease (UCD) is localized and carries an excellent prognosis, whereas multicentric Castleman disease (MCD) is a systemic disease occurring most commonly in the setting of HIV infection and is associated with human herpesvirus 8. MCD has been associated with considerable morbidity and mortality, and the therapeutic landscape for its management continues to evolve.
Methods
The available medical literature on UCD and MCD was reviewed. The clinical presentation and pathological diagnosis of Castleman disease was reviewed, along with associated disorders such as certain malignancies and autoimmune complications.
Results
Surgical resection remains the standard therapy for UCD, while systemic therapies are required for the management of MCD. Rituximab monotherapy is the mainstay of therapy; however, novel therapies targeting interleukin 6 may represent a treatment option in the near future. Antiviral strategies as well as single-agent and combination chemotherapy with glucocorticoids are established systemic therapies. The management of Castleman disease also requires careful attention to potential concomitant infections, malignancies, and associated syndromes.
Conclusions
UCD and MCD constitute uncommon but well-defined clinicopathologic entities. Although UCD is typically well controlled with local therapy, MCD continues to pose formidable challenges in management. We address historical chemotherapy-based approaches to this disease as well as recently developed targeted therapies, including rituximab and siltuximab, that have improved the outcome for newly diagnosed patients. Ongoing research into the management of MCD is needed.
References
1.
CastlemanB., TowneV.. CASE records of the Massachusetts General Hospital weekly clinicopathological exercises: case 40011.N Engl J Med.1954; 250(1): 26–30.
KellerA.R., HochholzerL., CastlemanB.. Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations.Cancer.1972; 29(3): 670–683.
4.
HerradaJ., CabanillasF., RiceL.. The clinical behavior of localized and multicentric Castleman disease.Ann Intern Med.1998; 128(8): 657–662.
5.
ScottD., CabralL., HarringtonW.J.Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide.Am J Hematol.2001; 66(2): 148–150.
6.
OksenhendlerE., BoulangerE., GalicierL.. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease.Blood.2002; 99(7): 2331–2336.
7.
BélecL., MohamedA.S., AuthierF.J.. Human herpesvirus 8 infection in patients with POEMS syndrome-associated multicentric Castleman's disease.Blood.1999; 93(11): 3643–3653.
8.
ChangY., CesarmanE., PessinM.S.. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma.Science.1994; 266(5192): 1865–1869.
9.
SoulierJ., GrolletL., OksenhendlerE.. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease.Blood.1995; 86(4): 1276–1280.
10.
AnJ., LichtensteinA.K., BrentG.. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element.Blood.2002; 99(2): 649–654.
11.
KellerS.A., Hernandez-HopkinsD., ViderJ.. NF-kappaB is essential for the progression of KSHV- and EBV-infected lymphomas in vivo.Blood.2006; 107(8): 3295–3302.
12.
PolizzottoM.N., UldrickT.S., WangV.. Human and viral interleukin-6 and other cytokines in Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.Blood.2013; 122(26): 4189–4198.
13.
StebbingJ., AdamsC., SanittA.. Plasma HHV8 DNA predicts relapse in individuals with HIV-associated multicentric Castleman disease.Blood.2011; 118(2): 271–275.
14.
Newsom-DavisT., BowerM., WildfireA.. Resolution of AIDS-related Castleman's disease with anti-CD20 monoclonal antibodies is associated with declining IL-6 and TNF-alpha levels.Leuk Lymphoma.2004; 45(9): 1939–1941.
15.
BowerM., VeraitchO., SzydloR.. Cytokine changes during rituximab therapy in HIV-associated multicentric Castleman disease.Blood.2009; 113(19): 4521–4524.
16.
CarboneA., De PaoliP., GloghiniA.. KSHV-associated multicentric Castleman disease: A tangle of different entities requiring multitarget treatment strategies.Int J Cancer.2014. [Epub ahead of print].
17.
FerryJ., HarrisN.. Atlas of Lymphoid Hyperplasia and Lymphoma.Philadelphia: WB Saunders; 1997.
18.
DupinN., DissT.L., KellamP.. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.Blood.2000; 95(4): 1406–1412.
19.
IsaacsonP., CampoE., HarrisN.. Large B-cell lymphoma arising in HHV8–associated multicentric Castleman disease. In: SwerlowS., CampoE., HarrisN.. eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.Lyon, France: IARC;2008: 258.
20.
ChanJ.K.. Newly available antibodies with practical applications in surgical pathology.Int J Surg Pathol.2013; 21(6): 553–572.
21.
SatoY., KojimaM., TakataK.. Systemic IgG4-related lymphadenopathy: a clinical and pathologic comparison to multicentric Castleman's disease.Mod Pathol.2009; 22(4): 589–599.
22.
CheukW., ChanJ.K.. Lymphadenopathy of IgG4-related disease: an underdiagnosed and overdiagnosed entity.Semin Diagn Pathol.2012; 29(4): 226–234.
23.
TalatN., BelgaumkarA.P., SchulteK.M.. Surgery in Castleman's disease: a systematic review of 404 published cases.Ann Surg.2012; 255(4): 677–684.
ChronowskiG.M., HaC.S., WilderR.B.. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy.Cancer.2001; 92(3): 670–676.
26.
de VriesI.A., van AchtM.M., DemeyereT.. Neoadjuvant radiotherapy of primary irresectable unicentric Castleman's disease: a case report and review of the literature.Radiat Oncol.2010; 5: 7.
MatthiesenC., RamgopolR., SeaveyJ.. Intensity modulated radiation therapy (IMRT) for the treatment of unicentric Castlemans disease: a case report and review of the use of radiotherapy in the literature.Radiol Oncol.2012; 46(3): 265–270.
29.
MirandaF.A., FariaV.H., ArrudaG.V.. Radiation therapy in the treatment of unicentric Castleman's disease.J Bras Pneumol.2013; 39(1): 116–118.
30.
NeuhofD., DebusJ.. Outcome and late complications of radiotherapy in patients with unicentric Castleman disease.Acta Oncol.2006; 45(8): 1126–1131.
31.
NohO.K., LeeS.W., LeeJ.W.. Cases report of unicentric Castleman's disease: revisit of radiotherapy role.Radiat Oncol J.2013; 31(1): 48–54.
32.
FrizzeraG., PetersonB.A., BayrdE.D.. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients.J Clin Oncol.1985; 3(9): 1202–1216.
33.
MylonaE.E., BaraboutisI.G., LekakisL.J.. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.AIDS Rev.2008; 10(1): 25–35.
34.
BowerM., Newsom-DavisT., NareshK.. Clinical features and outcome in HIV-associated multicentric Castleman's disease.J Clin Oncol.2011; 29(18): 2481–2486.
35.
BowerM.. How I treat HIV-associated multicentric Castleman disease.Blood.2010; 116(22): 4415–4421.
36.
ZietzC., BognerJ.R., GoebelF.D.. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS.N Engl J Med.1999; 340(24): 1923–1924.
37.
SummerfieldG.P., TaylorW., BellinghamA.J.. Hyaline-vascular variant of angiofollicular lymph node hyperplasia with systemic manifestations and response to corticosteroids.J Clin Pathol.1983; 36(9): 1005–1011.
38.
WeisenburgerD.D., NathwaniB.N., WinbergC.D.. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases.Hum Pathol.1985; 16(2): 162–172.
39.
StanleyM.W., FrizzeraG., DehnerL.P.. Castleman's disease, plasma-cell type. Diagnosis of central nervous system involvement by cerebrospinal fluid cytology.Acta Cytol.1986; 30(5): 481–486.
BowneW.B., LewisJ.J., FilippaD.A.. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature.Cancer.1999; 85(3): 706–717.
42.
ParkJ.B., HwangJ.H., KimH.. Castleman disease presenting with jaundice: a case with the multicentric hyaline vascular variant.Korean J Intern Med.2007; 22(2): 113–117.
43.
OksenhendlerE., DuarteM., SoulierJ.. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients.AIDS.1996; 10(1): 61–67.
44.
ColleoniG.W., DuarteL.C., KerbauyF.R.. 2-chloro-deoxyadenosine induces durable complete remission in Castleman's disease but may accelerate its transformation to non-hodgkin's lymphoma.Acta Oncol.2003; 42(7): 784–787.
LoiS., GoldsteinD., ClezyK.. Castleman's disease and HIV infection in Australia.HIV Med.2004; 5(3): 157–162.
47.
UldrickT.S., PolizzottoM.N., O'MahonyD.. Rituximab combined with liposomal doxorubicin (R-Dox) in HIV-infected patients with severe Kaposi sarcoma-associated herpes virus (KSHV) associated multicentric Castleman disease (MCD).Infect Agent Cancer.2010; 5(Suppl 1): A72.
48.
SeoH.Y., KimE.B., KimJ.W.. Complete remission in a patient with human herpes virus-8 negative multicentric Castleman disease using CHOP chemotherapy.Cancer Res Treat.2009; 41(2): 104–107.
49.
LeeJ.H., KwonK.A., LeeS.. Multicentric Castleman disease complicated by tumor lysis syndrome after systemic chemotherapy.Leuk Res.2010; 34(1): e42–e45.
50.
GerardL., BerezneA., GalicierL.. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB trial.J Clin Oncol.2007; 25(22): 3350–3356.
MarracheF., LarrocheC., MemainN.. Prolonged remission of HIV-associated multicentric castelman's disease with an anti-CD20 monoclonal antibody as primary therapy.AIDS.2003; 17(9): 1409–1410.
55.
PowlesT., StebbingJ., MontotoS.. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease.Blood.2007; 110(12): 4132–4133.
56.
Cervera GrauJ.M., Galiana EsquerdoG., Llorca FerrandizC.. Complete remission in a pancytopenic HIV negative, HHV-8 positive patient with multicentric Castleman's disease induced with anti-CD20.Clin Transl Oncol.2006; 8(7): 540–541.
57.
NicoliP., FamiliariU., BosaM.. HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma.Int J Hematol.2009; 90(3): 392–396.
58.
LawA.B., RyanG., LadeS.. Development of Kaposi's sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient.Int J Hematol.2010; 91(2): 347–349.
59.
IdeM., KawachiY., IzumiY.. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.Eur J Haematol.2006; 76(2): 119–123.
60.
KurzrockR., VoorheesP.M., CasperC.. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-hodgkin lymphoma, multiple myeloma, or Castleman disease.Clin Cancer Res.2013; 19(13): 3659–3670.
61.
CasperC., VoorheesP.M., FayadL.E.. An open-label, phase 2, multicenter study of the safety of long-term treatment with siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman's disease.Blood.2013; 122(21): 1806–1806.
62.
CasperC., MunshiN., KeX.. A multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman's disease.Blood.2013; 122(21): 505–505.
MuzesG., SiposF., CsomorJ.. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.APMIS.2013; 121(7): 668–674.
65.
NagaoA., NakazawaS., HanabusaH.. Short-term efficacy of the IL6 receptor antibody tocilizumab in patients with HIV-associated multicentric Castleman disease: report of two cases.J Hematol Oncol.2014; 7(1): 10-8722-7-10.
66.
BottieauE., ColebundersR., SchroyensW.. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy.Acta Clin Belg.2000; 55(2): 97–101.
67.
UldrickT.S., PolizzottoM.N., AlemanK.. High-dose zidovudine plus valganciclovir for kaposi sarcoma herpesvirus-associated multicentric Castleman disease: a pilot study of virus-activated cytotoxic therapy.Blood.2011; 117(26): 6977–6986.
68.
SenanayakeS., KellyJ., LloydA.. Multicentric Castleman's disease treated with antivirals and immunosuppressants.J Med Virol.2003; 71(3): 399–403.
69.
SchulteK.M., TalatN.. Castleman's disease–a two compartment model of HHV8 infection.Nat Rev Clin Oncol.2010; 7(9): 533–543.
70.
CasperC., NicholsW.G., HuangM.L.. Remission of HHV-8 and HIV-associated multicentric Castleman disease with ganciclovir treatment.Blood.2004; 103(5): 1632–1634.
71.
BerezneA., AgbalikaF., OksenhendlerE.. Failure of cidofovir in HIV-associated multicentric Castleman disease.Blood.2004; 103(11): 4368–4369.
72.
RajkumarS.V., RichardsonP.G., HideshimaT.. Proteasome inhibition as a novel therapeutic target in human cancer.J Clin Oncol.2005; 23(3): 630–639.
73.
HessG., WagnerV., KreftA.. Effects of bortezomib on pro-inflammatory cytokine levels and transfusion dependency in a patient with multicentric Castleman disease.Br J Haematol.2006; 134(5): 544–545.
74.
KhanA.A., SirajF., BhargavaM.. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.BMJ Case Rep.2012; 2012: 10.1136/bcr-2012-007646.
75.
SobasM.A., Alonso VenceN., Diaz AriasJ.. Efficacy of bortezomib in refractory form of multicentric Castleman disease associated to poems syndrome (MCD-POEMS variant).Ann Hematol.2010; 89(2): 217–219.
76.
YuanZ.G., DunX.Y., LiY.H.. Treatment of multicentric Castleman's disease accompanying multiple myeloma with bortezomib: a case report.J Hematol Oncol.2009; 2: 19-8722-2-19.
77.
CasqueroA., BarrosoA., Fernandez GuerreroM.L.. Use of rituximab as a salvage therapy for HIV-associated multicentric Castleman disease.Ann Hematol.2006; 85(3): 185–187.
78.
CorbellinoM., BestettiG., ScalamognaC.. Long-term remission of kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy.Blood.2001; 98(12): 3473–3475.
79.
TurcotteL.M., CorrellC.K., ReedR.C.. Sustained remission of severe multicentric Castleman disease following multiagent chemotherapy and tocilizumab maintenance.Pediatr Blood Cancer.2014; 61(4): 737–739.
80.
SongS.N., TomosugiN., KawabataH.. Down-regulation of hepcidin resulting from long-term treatment with an anti-IL-6 receptor antibody (tocilizumab) improves anemia of inflammation in multicentric Castleman disease.Blood.2010; 116(18): 3627–3634.
LarrocheC., CacoubP., SoulierJ.. Castleman's disease and lymphoma: report of eight cases in HIV-negative patients and literature review.Am J Hematol.2002; 69(2): 119–126.
83.
KesslerE.. Multicentric giant lymph node hyperplasia. A report of seven cases.Cancer.1985; 56(10): 2446–2451.
84.
Abdel-ReheimF.A., KossW., RappaportE.S.. Coexistence of Hodgkin's disease and giant lymph node hyperplasia of the plasma-cell type (Castleman's disease).Arch Pathol Lab Med.1996; 120(1): 91–96.
McAloonE.J.. Hodgkin's disease in a patient with Castleman's disease.N Engl J Med.1985; 313(12): 758.
87.
SalettiP., GhielminiM., ScaliG.. Hodgkin's and Castleman's disease in a patient with systemic mastocytosis.Ann Hematol.1999; 78(2): 97–100.
88.
Zarate-OsornoA., MedeirosL.J., DanonA.D.. Hodgkin's disease with coexistent Castleman-like histologic features. A report of three cases.Arch Pathol Lab Med.1994; 118(3): 270–274.
89.
ParraviciniC., CorbellinoM., PaulliM.. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease.Am J Pathol.1997; 151(6): 1517–1522.
90.
AndhavarapuS., JiangL.. POEMS syndrome and Castleman disease.Blood.2013; 122(2): 159.
91.
DispenzieriA.. POEMS syndrome: 2011 update on diagnosis, risk-stratification, and management.Am J Hematol.2011; 86(7): 591–601.
92.
BélecL., AuthierF.J., MohamedA.S.. Antibodies to human herpesvirus 8 in POEMS (polyneuropathy, organomegaly, endocrinopathy, M protein, skin changes) syndrome with multicentric Castleman's disease.Clin Infect Dis.1999; 28(3): 678–679.
93.
AndrikoJ.W., KaldjianE.P., TsokosM.. Reticulum cell neoplasms of lymph nodes: a clinicopathologic study of 11 cases with recognition of a new subtype derived from fibroblastic reticular cells.Am J Surg Pathol.1998; 22(9): 1048–1058.
94.
ChanA.C., ChanK.W., ChanJ.K.. Development of follicular dendritic cell sarcoma in hyaline-vascular Castleman's disease of the nasopharynx: tracing its evolution by sequential biopsies.Histopathology.2001; 38(6): 510–518.
95.
ChanJ.K., FletcherC.D., NaylerS.J.. Follicular dendritic cell sarcoma. clinicopathologic analysis of 17 cases suggesting a malignant potential higher than currently recognized.Cancer.1997; 79(2): 294–313.
FornelliA., MuredenA., EusebiV.. Follicular dendritic cell tumor and unusual vascular lesion in lymph node with Castleman's disease. Description of a case.Pathologica.1998; 90(2): 146–151.
98.
KatanoH., KanekoK., ShimizuS.. Follicular dendritic cell sarcoma complicated by hyaline-vascular type Castleman's disease in a schizophrenic patient.Pathol Int.1997; 47(10): 703–706.
99.
LeeI.J., KimS.C., KimH.S.. Paraneoplastic pemphigus associated with follicular dendritic cell sarcoma arising from Castleman's tumor.J Am Acad Dermatol.1999; 40 (2 pt 2): 294–297.
100.
LinO., FrizzeraG.. Angiomyoid and follicular dendritic cell proliferative lesions in Castleman's disease of hyaline-vascular type: a study of 10 cases.Am J Surg Pathol.1997; 21(11): 1295–1306.
101.
KaplanI., HodakE., AckermanL.. Neoplasms associated with paraneoplastic pemphigus: a review with emphasis on non-hematologic malignancy and oral mucosal manifestations.Oral Oncol.2004; 40(6): 553–562.
